Macular retinal edema

Summary

Macular retinal edema (MONDO:0003005) is a disease and 213 clinical trials. Top therapeutic interventions include bevacizumab, aflibercept, and ranibizumab. A subtype of macular degeneration — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 213

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	macular retinal edema
Mondo ID	MONDO:0003005
DOID	DOID:4449
NCIT	C35468
SNOMED CT	37231002
UMLS	C0271051
MedGen	75732
Anatomy (UBERON)	UBERON:0000053
Is cancer (heuristic)	no

Also known as: macula lutea retinal edema · macula lutea retinal oedema · macular edema · retinal edema of macula lutea · retinal oedema of macula lutea

Disease family

This is a subtype of macular degeneration. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal degeneration › macular degeneration › macular retinal edema

Related subtypes (8): vitelliform macular dystrophy, degeneration of macula and posterior pole, autosomal recessive bestrophinopathy, occult macular dystrophy, macular degeneration, early-onset, Stargardt disease, patterned macular dystrophy, isolated macular dystrophy

Subtypes (1): cystoid macular edema

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 213.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	86
PHASE3	45
PHASE2	32
PHASE4	25
PHASE1	13
PHASE1/PHASE2	7
PHASE2/PHASE3	4
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00411970	PHASE4	COMPLETED	20- Versus 23- Gauge System for Pars Plana Vitrectomy
NCT00566761	PHASE4	TERMINATED	Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
NCT00682240	PHASE4	COMPLETED	Morphological and Functional Retinal Changes Following Retinal Photocoagulation
NCT00801866	PHASE4	WITHDRAWN	Avastin for Post-photocoagulation Macular Edema
NCT00804206	PHASE4	TERMINATED	Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation
NCT00918554	PHASE4	TERMINATED	Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis
NCT01277302	PHASE4	COMPLETED	A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
NCT01315275	PHASE4	COMPLETED	A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
NCT01395069	PHASE4	COMPLETED	Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery
NCT01427751	PHASE4	COMPLETED	Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
NCT01795209	PHASE4	TERMINATED	Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
NCT01827722	PHASE4	UNKNOWN	Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
NCT01870440	PHASE4	COMPLETED	TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema
NCT01903720	PHASE4	COMPLETED	A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
NCT01939691	PHASE4	TERMINATED	Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
NCT02399657	PHASE4	UNKNOWN	Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema
NCT02559180	PHASE4	COMPLETED	Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
NCT02581995	PHASE4	COMPLETED	Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
NCT03056079	PHASE4	UNKNOWN	Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept
NCT03056092	PHASE4	UNKNOWN	Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab
NCT03211741	PHASE4	UNKNOWN	Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema
NCT03261635	PHASE4	COMPLETED	Ranibizumab Plus Indomethacin
NCT03355638	PHASE4	COMPLETED	Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
NCT03908307	PHASE4	COMPLETED	Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
NCT07090044	PHASE4	COMPLETED	Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
NCT06305416	PHASE3	RECRUITING	A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
NCT06595355	PHASE2/PHASE3	RECRUITING	Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
NCT00106132	PHASE3	COMPLETED	Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
NCT00168298	PHASE3	COMPLETED	A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00168324	PHASE3	COMPLETED	A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00309192	PHASE3	COMPLETED	Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema
NCT00344253	PHASE3	COMPLETED	Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
NCT00347711	PHASE3	WITHDRAWN	Bevacizumab and Retinal Vascular Occlusions
NCT00473330	PHASE3	COMPLETED	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
NCT00473382	PHASE3	COMPLETED	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
NCT00485836	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
NCT00486018	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
NCT00567697	PHASE3	COMPLETED	A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
NCT00642226	PHASE3	TERMINATED	Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
NCT00703235	PHASE2/PHASE3	UNKNOWN	Intravitreal Bevacizumab for Diabetic Macular Edema

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	12
AFLIBERCEPT	4	7
RANIBIZUMAB	4	7
TRIAMCINOLONE	4	5
BRIMONIDINE	4	4
NEPAFENAC	4	4
KETOROLAC	4	3
TRIAMCINOLONE ACETONIDE	4	3
BROMFENAC	4	2
DEXAMETHASONE	4	2
FARICIMAB	4	2
ACETAZOLAMIDE	4	1
ALCOHOL	4	1
BETAMETHASONE	4	1
DEXAMETHASONE SODIUM PHOSPHATE	4	1
DIFLUPREDNATE	4	1
EFALIZUMAB	4	1
FLUOCINOLONE ACETONIDE	4	1
INDOMETHACIN	4	1
LOTEPREDNOL ETABONATE	4	1
METHOTREXATE	4	1
PEGAPTANIB SODIUM	4	1
PREDNISOLONE ACETATE	4	1
ABICIPAR PEGOL	3	1
CONBERCEPT	3	1
INTERFERON BETA	3	1
OMEGA-3 FATTY ACIDS	3	1
TARCOCIMAB TEDROMER	3	1
FOSELUTOCLAX	2	1
GSK2798745	2	1